

Contents

Preface

xiii

1. Fluorogenic Derivatization Followed by HPLC Quantification and Final Identification of Proteins by HPLC-Tandem Mass Spectrometry (FD-LC-MS/MS) Method 1

Akiyo Koshiyama, Tomoko Ichibangase, and Kazuhiro Imai

1.1	Overview of the Method	1
1.2	Apparatus and Method	5
1.2.1	Apparatus	5
1.2.2	Method	5
1.3	Applications of the Method	7
1.3.1	Differential Analysis of Disease-Related Proteins in Livers of Hepatitis-Infected Mouse Model	7
1.3.2	Differential Analysis of Breast Cancer-Related Proteins in Comparison among Breast Cancer Cells and a Normal Epithelial Cell	8
1.3.3	Differential Analysis of Age-Related Proteins in Small Regions of Mouse Brain	10
1.3.4	Differential Analysis of Skeletal Muscle Proteins in Fast Thoroughbred Horses	11
1.4	Conclusion	12

2. Two-Dimensional Difference Gel Electrophoresis 17

Viola Ruddat

2.1	Introduction	17
2.2	Two-Dimensional Difference Gel Electrophoresis	18
2.2.1	Minimal Dyes	19
2.2.2	Saturation Dyes	19
2.3	Quantitative Aspects of 2D DIGE	20
2.4	Application Examples	21
2.4.1	Cancer-Related Research	22

2.4.2	Other Diseases	23
2.4.3	Agricultural Research	23
2.4.4	DIGE and RNA	23
2.4.5	Drug Studies	24
2.4.6	Stem Cell Research	24
2.4.7	Biopharmaceutical: Quality Control and Process Development	25
2.5	Special Applications	27
2.5.1	Pre-Fractionation	27
2.5.2	DIGE and Sample Preparation	27
2.5.3	Cell Surface Labeling with 2D-DIGE	28
2.5.4	Membrane Proteins	28
2.5.5	Study of Redox Potential	28
2.6	Conclusion	29
3.	Mass Spectrometry Utilizing Isotope-Coded Affinity Tag Reagents	35
	<i>Naoyuki Yamada</i>	
3.1	Introduction	35
3.2	ICAT Reagents	36
3.2.1	Original ICAT Reagent (First-Generation)	36
3.2.2	Cleavable ICAT (Second-Generation)	38
3.3	Methods	39
3.3.1	Denaturing and Reducing the Proteins	39
3.3.2	Labeling with Cleavable ICAT Reagents	40
3.3.3	Separation of Labeled Proteins by SDS-PAGE and In-Gel Digestion by Trypsin	40
3.3.4	Cation-Exchange Chromatography of the Cleavable ICAT-Labeled Peptides	40
3.3.5	Avidin-Affinity Chromatography and Cleavage of Biotin Moiety	41
3.3.6	Mass Spectrometry	41
3.3.7	Sequence Database Search for Identification and Protein Quantitation	42
4.	Proteomic Analyses of Post-Translational Modifications	45
	<i>Wei-Chi Ku and Yasushi Ishihama</i>	
4.1	Introduction	45
4.2	Proteomic Approaches for PTM Studies	46

4.2.1	Acetylation	48
4.2.2	Glycosylation	49
4.2.3	S-Nitrosylation	50
4.2.4	Phosphorylation	51
4.2.5	Ubiquitylation	52
4.3	MS-Based Analyses of Protein Phosphorylation	53
4.3.1	Enrichment of Phosphorylated Proteins or Peptides	53
4.3.1.1	Immobilized metal ion affinity chromatography	55
4.3.1.2	Hydroxy acid-modified metal oxide chromatography	55
4.3.1.3	β -Elimination and Michael addition	56
4.3.2	Application of HAMMOG in Phosphoproteomic Studies	57
4.3.3	Sequencing and Site-Determination of Phosphopeptides by MS	57
4.4	Concluding Remarks	58
5.	Cardiovascular Proteomic Analysis	67
	<i>Toru Suzuki and Ryozi Nagai</i>	
5.1	Introduction	68
5.2	Proteomic Analysis of Intracellular Proteins	69
5.3	Proteomic Analysis of Extracellular Proteins	74
5.4	Conclusions: Implications and Lessons Learned	78
6.	The Proteome in Neurodegenerative Diseases	85
	<i>Teruyuki Tsuji, Masahiro Aoki, and Shun Shimohama</i>	
6.1	Introduction	85
6.2	Biological Samples	88
6.3	Sample Separation	89
6.4	MS Techniques	90
6.5	Data Analysis	91
6.6	Aging and Dementia: General Aspects	92
6.7	The Aging Brain	93
6.8	Neurobiology of Aging and Cognitive Decline	95
6.9	Proteomics of CSF and Other Body Fluids	96
6.10	Neuroproteomics in the Study of CSF in Neurodegenerative Disorders	97

6.11	New Approach in Clinical Neuroproteomics: Protein Co-Expression Analysis of Human Samples from Brain, CSF, Serum, and Urine	100
6.11.1	Introduction	100
6.11.2	Materials and Methods	101
6.11.2.1	Samples	101
6.11.2.2	Sample preparation	101
6.11.2.3	2DE gel electrophoresis	102
6.11.2.4	Gel scanning and image analysis	102
6.11.2.5	Protein identification by mass spectrometry and database analysis	103
6.11.3	Results	103
6.11.3.1	Identification of proteins co-expressed in brain and serum	103
6.11.3.2	Identification of proteins co-expressed in brain and CSF	103
6.11.3.3	Identification of proteins co-expressed in brain and urine	107
6.11.3.4	Identification of proteins co-expressed in serum and CSF	107
6.12	Conclusions and Outlook	108
7.	Liver Disease-Related Proteomics	121
	<i>Hirofumi Uto, Yoichiro Takami, Shuji Kanmura, and Hirohito Tsubouchi</i>	
7.1	Introduction	122
7.2	Diagnostic Biomarkers for Liver Disease Used Currently in a Clinical Setting	123
7.3	Quantitative Proteomic Techniques for Liver Diseases	124
7.3.1	2D-DIGE	126
7.3.2	ProteinChip SELDI and ClinProt®	127
7.3.2.1	ProteinChip SELDI	128
7.3.2.2	ClinProt®	130
7.3.3	Isotope Labeling of Proteins with SILAC, ICAT, and NBS Methods	130
7.3.3.1	Cleavable isotope-coded affinity tags	130

7.3.3.2	Stable isotope labeling with amino acids in cell culture	131
7.3.3.3	NBS labeling method	132
7.3.3.4	Isobaric tagging for relative and absolute quantitation (iTRAQ)	134
7.4	Conclusion	134
8.	Respiratory Disease-Related Proteome	143
	<i>Masahiro Seike and Akihiko Gemma</i>	
8.1	Introduction	143
8.2	Lung Cancer	144
8.2.1	Cell Lines	144
8.2.2	Tumor Tissue	144
8.2.3	Serum/Plasma	145
8.2.4	Pleural Effusion and Urine	146
8.3	Diffuse Lung Disease	147
9.	Renal Disease-Related Proteome	149
	<i>Shinya Kaname and Tadashi Yamamoto</i>	
9.1	Overview of and Update on Proteomic Analysis for Renal Diseases	149
9.2	Samples and Methodologies of Proteomic Analysis for Renal Disease	151
9.2.1	Renal Tissues	151
9.2.1.1	Normal kidney tissues	151
9.2.1.2	Disease kidney tissues (especially human kidney biopsy samples)	153
9.2.2	Urine Proteomics	154
9.2.2.1	Database of urinary proteome	156
9.2.2.2	Proteomic analysis of urinary exosomes and its problems	156
9.2.3	Blood (Plasma, Serum)	157
9.2.4	Renal Cells	157
9.3	Applications of Proteomics to Various Renal Diseases	158
9.3.1	Acute Kidney Injury (AKI)	158
9.3.1.1	Animal models	158
9.3.1.2	Clinical studies	159

9.3.2	Tubular Disorders	159
9.3.3	Diabetic Nephropathy	160
9.3.4	IgA Nephropathy and Other Glomerular Diseases	161
9.3.5	Chronic Kidney Disease and Dialysis Patients	163
9.3.6	Renal Allograft Rejection	164
10.	Aging-Related Proteome	175
	<i>Tosifusa Toda</i>	
10.1	Introduction	176
10.2	Two-Dimensional Gel Electrophoresis (2-DE)-Based Quantitative Proteome Analysis of Replicative Aging	177
10.2.1	Preparation of Cell Proteins for Analyzing Replicative Aging	178
10.2.2	Two-Dimensional Gel Electrophoresis	179
10.2.3	Silver Staining and CBB Staining of 2-D Gel	179
10.2.4	Quantitative Analysis of Protein Spots by Image Processing	180
10.2.5	Protein Identification	181
10.2.6	Expression Profiling of Protein in Normal Human Diploid Fibroblasts, TIG-3, with Replicative Aging	181
10.3	Proteome Research on Post-Mitotic Cell Aging in Brain Tissues	183
10.3.1	Preparation of Tissue Proteins for Analyzing Post-Mitotic Cell Aging	183
10.3.2	2-D Gel Electrophoresis	184
10.3.3	Visualization of Protein Spots by Staining	184
10.3.4	Quantitative Spot Analysis by Image Processing	184
10.3.5	Expression Profiling of Protein in Mouse Brain with Aging	185
11.	Phosphoproteomics of Tumor Cell Lines	189
	<i>Hisafumi Okabe</i>	
11.1	Introduction	189

11.2	Proteomic Analysis of Phosphorylated Peptides	190
11.3	Phosphoproteomic Analyses of Three Distinct Tumor Cell Lines	191
11.4	Functional Annotation of the Identified Phosphoproteins	192
11.5	Phosphorylation Status of Signaling Proteins and Representative Proteins and Changes upon Nocodazole Treatment in Three Tumor Cell Lines	196
11.6	Nocodazole-Induced Phosphoproteins Common to Three Distinct Tumor Cell Lines	199
11.7	A Time Course Analysis of Nocodazole-Induced Phosphorylations	199
11.8	Conclusion	201
12.	HCV Infection and Mitochondria Proteomics	205
	<i>Kyoji Moriya, Takeya Tsutsumi, Hideyuki Miyoshi, and Kazuhiko Koike</i>	
12.1	HCV	206
12.2	HCV Genome	206
12.3	HCV Core Protein	207
12.4	Transgenic Mice Model	208
12.5	HCV Core Transgenic Mice	209
12.6	HCV Infection and Metabolism	210
12.7	Steatosis and Mitochondria	211
12.8	Virus Infection and Mitochondria Function	212
12.9	HCV and Reactive Oxygen Species	212
12.10	Mitochondria	215
12.11	HCV and Prohibitin	215
12.12	LC-Tandem Mass Spectrometry	216
12.13	Immunity	217
13.	Identification of Biomarkers of Infectious Disease Using Surface-Enhanced Laser Desorption/Ionisation Mass Spectrometry	223
	<i>Shea Hamilton and Paul R. Langford</i>	
13.1	Introduction	223
13.2	SELDI Technology	225
13.3	Considerations for a Successful SELDI Study	226

13.4	Diseases or Syndromes Associated with Viral Infection	229
13.4.1	Hepatitis B and C Viruses and Hepatocellular Carcinoma	229
13.4.2	Epstein-Barr Virus and Nasopharyngeal Carcinoma	235
13.4.3	Chronic Fatigue Syndrome	236
13.4.4	HIV-1 Associated Dementia (HAD)	237
13.4.5	Human Papillomavirus and Oral Squamous Cell Carcinomas	238
13.4.6	Porcine Reproductive and Respiratory Disease Syndrome	238
13.5	Diseases Associated with Bacterial Infection	239
13.5.1	Tuberculosis	239
13.5.2	Sepsis	240
13.5.3	Respiratory Diseases	240
13.5.4	Intra-Amniotic Infection	243
13.5.5	Bacterial Peritonitis	245
13.6	Parasitic Infections	245
13.6.1	<i>Fasciola Hepatica</i>	245
13.6.2	Cestode Infection of the Brine Shrimp	246
13.6.3	Chaga's Disease	247
13.6.4	<i>Taenia Solium</i>	248
13.7	Prion Disease	249
13.8	Hepcidin Measurement	250
13.10	Concluding Remarks	265
14.	Quantitative Proteomic Analysis of HIV Infection	275
	<i>Li Juan Fu and Sam F. Y. Li</i>	
14.1	Introduction	275
14.2	HIV Proteomic Research	276
14.2.1	T Cells	276
14.2.2	Macrophages	278
14.2.3	Cerebrospinal Fluid	279
14.2.4	Plasma	280
14.2.5	Cervical Lavage Samples	281
14.3	Discussion and Conclusion	281
	<i>Index</i>	289